S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
NASDAQ:SONN

Sonnet BioTherapeutics (SONN) Stock Price, News & Analysis

$1.70
+0.03 (+1.80%)
(As of 04/17/2024 ET)
Today's Range
$1.70
$1.73
50-Day Range
$1.45
$2.26
52-Week Range
$1.08
$26.40
Volume
9,972 shs
Average Volume
93,581 shs
Market Capitalization
$5.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$88.70

Sonnet BioTherapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
5,117.6% Upside
$88.70 Price Target
Short Interest
Healthy
16.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.50mentions of Sonnet BioTherapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.26 out of 5 stars

SONN stock logo

About Sonnet BioTherapeutics Stock (NASDAQ:SONN)

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.

SONN Stock Price History

SONN Stock News Headlines

The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
BTIG Keeps Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)
Dow Falls Over 100 Points; Alphabet Shares Tumble After Q3 Results
See More Headlines
Receive SONN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sonnet BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
4/17/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SONN
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$88.70
High Stock Price Target
$147.40
Low Stock Price Target
$30.00
Potential Upside/Downside
+5,117.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-18,830,000.00
Net Margins
-11,187.19%
Pretax Margin
-11,187.19%

Debt

Sales & Book Value

Annual Sales
$150,000.00
Book Value
($0.13) per share

Miscellaneous

Free Float
3,008,000
Market Cap
$5.22 million
Optionable
Not Optionable
Beta
0.64
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Pankaj Mohan Ph.D. (Age 59)
    Founder, Chairman, CEO & President
    Comp: $927k
  • Dr. John K. Cini Ph.D. (Age 71)
    Chief Scientific Officer & Co-Founder
    Comp: $602.48k
  • Mr. Jay Cross (Age 54)
    Chief Financial Officer
    Comp: $603.42k
  • Mr. Donald J. Griffith CPA (Age 75)
    CPA, Controller & Director
    Comp: $134.05k
  • Ms. Susan Dexter (Age 69)
    Chief Technical Officer
  • Dr. Richard T. Kenney FACP (Age 66)
    M.D., Chief Medical Officer
  • Mr. Manuel Dafonseca
    Head of Clinical Operations

SONN Stock Analysis - Frequently Asked Questions

Should I buy or sell Sonnet BioTherapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sonnet BioTherapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SONN shares.
View SONN analyst ratings
or view top-rated stocks.

What is Sonnet BioTherapeutics' stock price target for 2024?

3 brokers have issued twelve-month price targets for Sonnet BioTherapeutics' shares. Their SONN share price targets range from $30.00 to $147.40. On average, they anticipate the company's stock price to reach $88.70 in the next twelve months. This suggests a possible upside of 5,117.6% from the stock's current price.
View analysts price targets for SONN
or view top-rated stocks among Wall Street analysts.

How have SONN shares performed in 2024?

Sonnet BioTherapeutics' stock was trading at $1.74 at the beginning of 2024. Since then, SONN shares have decreased by 2.3% and is now trading at $1.70.
View the best growth stocks for 2024 here
.

Are investors shorting Sonnet BioTherapeutics?

Sonnet BioTherapeutics saw a drop in short interest in March. As of March 31st, there was short interest totaling 452,200 shares, a drop of 18.9% from the March 15th total of 557,500 shares. Based on an average daily trading volume, of 101,000 shares, the days-to-cover ratio is presently 4.5 days. Approximately 16.3% of the shares of the stock are sold short.
View Sonnet BioTherapeutics' Short Interest
.

When is Sonnet BioTherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our SONN earnings forecast
.

How were Sonnet BioTherapeutics' earnings last quarter?

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) released its quarterly earnings data on Wednesday, February, 14th. The company reported ($0.31) earnings per share for the quarter. The company earned $0.02 million during the quarter. Sonnet BioTherapeutics had a negative trailing twelve-month return on equity of 519.54% and a negative net margin of 11,187.19%.

When did Sonnet BioTherapeutics' stock split?

Sonnet BioTherapeutics shares reverse split on Friday, September 1st 2023. The 1-22 reverse split was announced on Friday, September 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Sonnet BioTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sonnet BioTherapeutics investors own include Gevo (GEVO), Sorrento Therapeutics (SRNE), Boxlight (BOXL), T2 Biosystems (TTOO), Biocept (BIOC), iBio (IBIO), Trevena (TRVN), Vaxart (VXRT), ADMA Biologics (ADMA) and Advanced Micro Devices (AMD).

How do I buy shares of Sonnet BioTherapeutics?

Shares of SONN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SONN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners